1. Scrip
  2. >>R&D

Bluebird Bio Gets Relief, But Gene Therapy Hurdles Remain

Sickle Cell Patient’s AML Likely Unrelated To LentiGlobin

 
• By Alaric DeArment

The jury is still out on the case of MDS and some remaining questions regarding the AML case may still hinder commercial uptake.

Sickle cell anemia, 3D illustration showing blood vessel with normal and deformated crescent-like red blood cells
An analyses by bluebird bio probably rules out its gene therapy as the culprit behind a patient in its SCD study developing acute myeloid leukemia • Source: Shutterstock

bluebird bio said a case of acute myeloid leukemia (AML) in a patient receiving its gene therapy for sickle cell disease (SCD), which was first disclosed in February, probably was not connected to the therapy itself. The 10 March announcement dispersed a significant dark cloud hanging over the program but potential hurdles remain on the road ahead, including adoption of the gene therapy, LentiGlobin.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Ironwood To Consider All Options With Apraglutide Setback In SBS

 
• By Joseph Haas

With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

Amgen’s Imdelltra Sets The Pace In Small-Cell Lung Cancer

 
• By Andrew McConaghie

The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Amgen’s Imdelltra Sets The Pace In Small-Cell Lung Cancer

 
• By Andrew McConaghie

The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.